Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy
- 1 July 1995
- journal article
- clinical trial
- Published by Springer Nature in Osteoporosis International
- Vol. 5 (4) , 276-280
- https://doi.org/10.1007/bf01774018
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Immunoassay for urinary pyridinoline: The new marker of bone resorptionJournal of Bone and Mineral Research, 1993
- A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urineJournal of Bone and Mineral Research, 1992
- Desogestrel in hormone replacement therapy: long‐term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleedingEuropean Journal of Clinical Investigation, 1991
- Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosisJournal of Bone and Mineral Research, 1991
- Screening procedure for women at risk of developing postmenopausal osteoporosisOsteoporosis International, 1990
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- Effect of salcatonin given intranasally on early postmenopausal bone loss.BMJ, 1989
- The Risk of Breast Cancer after Estrogen and Estrogen–Progestin ReplacementNew England Journal of Medicine, 1989
- Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study.BMJ, 1989
- CYPROTERONE ACETATE, AN ALTERNATIVE GESTAGEN IN POSTMENOPAUSAL OESTROGEN/GESTAGEN THERAPYClinical Endocrinology, 1987